PARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric survey
While this survey is meant as hypotheses-generating, PrMN represent a rare but clinically relevant complication, particularly uncommon when PARPi are administered as first-line therapy. Their occurrence does not appear to be associated with the specific PARPi used or with BRCA mutation status. Early detection, monitoring, and identification of predictive factors are crucial as ovarian cancer outcomes improve and treatment exposure increases.
Authors
- Maria Rosaria Lamia
- Chiara Abeni
- Maria Cristina Petrella
- Vera Loizzi (ORCID: https://orcid.org/0000-0002-4006-6421)
- Maria Teresa Perri (ORCID: https://orcid.org/0000-0002-0222-656X)
- Margherita Turinetto
- Annamaria Ferrero (ORCID: https://orcid.org/0000-0002-2909-3699)
- Elio Coppola (ORCID: https://orcid.org/0000-0002-4118-5879)
- Cristina Angela Camnasio
- Carmine De Angelis (ORCID: https://orcid.org/0000-0003-1158-4630)
- G Cirigliano
- N Colombo
- Federica Villa (ORCID: https://orcid.org/0009-0005-5052-1079)
- Giuseppa Scandurra (ORCID: https://orcid.org/0000-0001-8025-581X)
- Giuseppe Caruso (ORCID: https://orcid.org/0000-0001-5501-1936)
- Patrizia Chiusolo (ORCID: https://orcid.org/0000-0002-1355-1587)
- Sabrina Chiara Cecere (ORCID: https://orcid.org/0000-0002-7915-1623)
- Serena Maria Boccia (ORCID: https://orcid.org/0000-0001-5434-1263)
- Serafina Mammoliti (ORCID: https://orcid.org/0000-0002-6560-0061)
- M. Destefanis (ORCID: https://orcid.org/0000-0003-1997-6751)
- D. Pellegrini (ORCID: https://orcid.org/0000-0002-8853-0617)
- Cláudia Marchetti (ORCID: https://orcid.org/0000-0001-7098-8956)
- Marisa Distefano (ORCID: https://orcid.org/0000-0002-7393-0941)
- Anna Fagotti (ORCID: https://orcid.org/0000-0001-5579-335X)
- Giorgio Valabrega (ORCID: https://orcid.org/0000-0001-5444-6305)
- Mario Giordano (ORCID: https://orcid.org/0000-0003-4224-636X)
- Valentina Lombardo (ORCID: https://orcid.org/0000-0002-0446-6436)
- Gennaro Cormio (ORCID: https://orcid.org/0000-0001-5745-372X)
- Vittoria Barberi
- S Pignata
Institutions
- IMT School for Advanced Studies Lucca (IT)
- Humanitas University (IT)
- Università degli Studi di Enna Kore (IT)
- University of Pavia (IT)
- Agostino Gemelli University Polyclinic (IT)
- Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari (IT)
- Ospedale Sant'Anna (IT)
- Alessandro Manzoni Hospital (IT)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Federico II University Hospital (IT)
- A. O. Ordine Mauriziano di Torino (IT)
- Istituto Tumori Bari (IT)
- National Cancer Institute (MY)
- Ospedale Cannizzaro (IT)
- Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo (IT)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Ospedale Pediatrico Giovanni XXIII (IT)
- Ospedale Policlinico San Martino (IT)
- Fondazione Poliambulanza Istituto Ospedaliero (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- University of Turin (IT)
- European Institute of Oncology (IT)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105903
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00